Skip to main content
. Author manuscript; available in PMC: 2015 Jan 12.
Published in final edited form as: J Invest Dermatol. 2014 Feb 12;134(8):2202–2211. doi: 10.1038/jid.2014.85

Figure 1. In all, 446 immune-related genes were profiled using NanoString technology, and a subset of 53 genes predicts clinical non-progression in two independent sets of patients.

Figure 1

In (a), a diagram describes the schema for selection of the 446 genes. (b) The clinical characteristics of patients in the training set. In (c), relative levels of mRNA expression for each sample are depicted according to the color scale shown, with each column representing a different patient sample and each row representing one of the 446 genes. Unsupervised hierarchical clustering was performed on both genes and samples. Patients who progressed are labeled in blue and those who did not are labeled in yellow. Blue indicates higher expression and yellow indicates lower expression of each gene in the color scale.